Pot stocks have been relatively flimsy this week since a report from Statistics Canada showed that cannabis consumption hasn’t changed much since the legal pot market was rolled out.
Why the U.S. can refocus its regulatory approach to pharmaceuticals, adapted from the one used in Europe, to better connect the value prescription drugs provide and their price.
Pitchbook recently released its 2018 results for cannabis related investments, and the data is impressive: 139 deals scooped up a whopping $881 million.